by Alex Kadhim
A comprehensive review from the ASTCT–NMDP ACCESS Initiative highlights persistent disparities in access to hematopoietic cell transplantation and CAR T therapy, revealing how race, age,...
by Alex Kadhim
A phase I study demonstrates that dual-targeted BCMA and GPRC5D CAR T therapy is feasible and active in relapsed/refractory multiple myeloma, achieving high response rates with manageable...
by ASTCT Talks and Oncology On the Go
In a cobranded episode between Oncology On the Go, hosted by CancerNetwork®, and the American Society for Transplantation and Cellular Therapy’s (ASTCT) program ASTCT Talks, Terri Lynn...
by Margy MacMillan
In this President’s Message, ASTCT President Margy MacMillan reflects on the mentors, colleagues, and relationships that shape careers in transplantation and cellular therapy. She highlights...
by Alex Kadhim
New research identifies NLRP6 as a critical regulator of donor T-cell activity after allogeneic hematopoietic cell transplantation, showing that loss of NLRP6 worsens acute graft-versus-host...
by Alex Kadhim
New research identifies donor-cell GATA3 as a key driver of intestinal graft-versus-host disease after hematopoietic cell transplantation, linking it to pathogenic T-cell activity, tissue damage,...